Month: March 2018

Eric Lefkofsky: An American Hero Amongst Us

Founded by one of the most well-known marketers known in chicago, Mr. Eric Lefkofski’s Tempus Labs continues to rank on the top 10 health tech start-ups list without fail. That is not easy! What makes this feat even more exceptional, is that Tempus Labs is a fledgling company of a mere 3-years of age, and has still made that list over similar companies that are much, much older! In fact, Tempus was the featured company on Eric Topal’s exclusive list focusing only on the best of the best in technological advancement.

In addition to being brilliant, Mr. Lefkoski has inspired many with his impassioned connections to nearly all of the NCI’S (National Cancer Institute) cancer centers nationwide. The NCI values his expertise tremendously and utilises the many services offered by Tempus Labs such as: tumor and germline DNA sequencing, liquid biopsying of cell-free DNA, RNA sequencing of tumors, immune system characterization of both patients and tumors, organoid cultures of tumors at a cellular level with drug testing, machine-learning of the myriads info collected, which is then organized and seamlessly ingrained into both the electronic medical record and imagery/pathology reports.

Thanks to Eric Lufkowski and the company he founded Tempus has changed the lives of many patients who had previously untreatable diseases. Untreatable, that is, until Tempus refined gene therepy and editing. Not too long thereafter, the FDA put its stamp of approval on this new methodology, enriching the lives of those with (or the potential risk of) extensive vision loss due to a certain gene mutation. Thanks to Mr. Lufkofski, this can now be treated effectively long before complete blindness sets in.

Lufkofski’s goals for the future includes skin cancer and atrial fibrillation technology that will highlight very detailed and specific characteristics; it is his goal to use this technology to zoom in on the exactly what treatments and which specialists are needed to improve patient conditions. He further hopes to develop advancements that hasten treatment times in the event of an outbreak or public health crises.

These are only a few of Eric Lufkowksis contributions so far to the the world in which we live. Not only is he an accomplished author who spreads his knowledge to any who seek it, but because of his brilliance and passion to help the sick, he has improved healthcare system and applications in ways never before seen. He is a philanthropist at heart, and by sheer genetics he gravitates toward helping the most vulnerable among us, including those who receive care from Lurie Childrens hospital in Chicago. Lefkovski also invests tremendous time,money and energy into his Lefkofky Foundation which desires to improve human rights, education, medicine, culture and art in order that all of our lives may be further enriched.

That’s Eric Lefkofsky. A generous man who naturally puts the needs of others before himself. He is truly the epitome of all that’s woven into what an american hero, icon and philanthropist should. And he has blazed an honorable trail for future generations to follow.

Contact Eric Lefkofsky:

Paul Mampilly Explains Why You Should Beware Of Amazon’s Moves

Amazon certainly has been a leading e-commerce innovator over the last 20 years, and many people have benefited from the immense services they offer. But while their company has been a great resource for retail shoppers and digital streaming customers, they’ve been a nightmare for certain companies and their stockholders. A particular area they’re now causing grave concern in is the healthcare industry because they’re now putting together a plan that could disrupt it altogether by changing how pharmaceuticals are distributed to consumers.

Paul Mampilly is an investor who’s taken great interest in Amazon’s development because he writes newsletters to thousands of followers that explain how you can buy stocks and which kind you should look into. What he’s saying about Amazon’s healthcare plans are that they’re going to cut out all the middlemen that normally come between a pharmaceutical and its delivery to a drug store shelf. This is a big deal because that middleman is where much of the main pharmacy companies and manufacturers profit from and it affects their stock prices. Amazon’s targeting of those stocks and bringing of transparency into the industry may be good for some middle class Americans who struggle to afford health insurance and prescription costs, but it’s bad for stockholders because this could cause a sudden downturn in stock prices that they may never recover from. Mampilly is urging his followers not to buy falling healthcare stocks even if they look like a very good deal.

Paul Mampilly has been writing newsletters at an independent investment advisory news company known as Banyan Hill for a couple years now, but he had made a name for himself on Wall Street for more than 20 years prior to that. He began his career at Deutsche Bank after receiving a bachelor’s degree in finance from Montclair State University, and he became a savvy investor after several years as an adept researcher. He became a major account manager for ING and Banker’s Trust in the years following this, and in 2006 he started directing hedge funds at Kinetics International Fund. In just the first few months he attracted so many clients to the firm that its AUM rose from $6 billion to $25 billion, and Barron’s gave him recognition for making annual returns on investments at 26%. He also won the competition at the Templeton Foundation while employed at the firm.

Paul Mampilly’s ultimate goal was not to help the Wall Street clients but instead to help the working people of America learn how to gain financial independence by investing on their own, so he left his New York office and moved down to a more smaller town in North Carolina in 2012. He stayed low key for a few years but then announced his newsletter at Banyan Hill in 2016 and shocked many of his initial readers when he mentioned the gains they could make in the stock market. But as many of them started putting his advice to use, they realized it was legitimate and many started raving about the gains they had made in user reviews. Mampilly is all about transparency and gives his readers an over-the-shoulder look at his investments so they can see how he runs them.